Bezacitinib

贝泽昔替尼

Report date: 2026/05/27 14:22:32
NME

Base Information

Drug NameBezacitinib
Drug Alias Name邦瑞替尼Bewintinib邦瑞顺OB-756
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJAK2 V617F inhibitorsTyrosine-protein kinase 2 inhibitorsApoptosis inducers +[4] 
TargetsJAK2 V617FTyrosine-protein kinase 2
Therapy Area/IndicationsGraft vs Host DiseaseDiabetes Mellitus, Type 1Primary Myelofibrosis +[7] 
Global Approved IndicationsPrimary Myelofibrosis
Approved Indications in ChinaPrimary Myelofibrosis
Original Approved Country/TerritoryMainland China
Original Approved Date2026/04/29
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHangzhou Huadong Pharmaceutical Group Biomedicine Co LtdHangzhou Aojin Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Bangshun Pharmaceutical Co LtdHangzhou Huadong Pharmaceutical Group Biomedicine Co Ltd
Inactive CompaniesHangzhou Aojin Biomedical Technology Co Ltd
Active IndicationsGraft vs Host DiseaseDiabetes Mellitus, Type 1Primary Myelofibrosis +[6] 
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A